company background image
MDP logo

Medexus Pharmaceuticals TSX:MDP Stock Report

Last Price

CA$2.55

Market Cap

CA$63.6m

7D

2.0%

1Y

26.2%

Updated

30 Oct, 2024

Data

Company Financials +

Medexus Pharmaceuticals Inc.

TSX:MDP Stock Report

Market Cap: CA$63.6m

Medexus Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Medexus Pharmaceuticals
Historical stock prices
Current Share PriceCA$2.55
52 Week HighCA$3.16
52 Week LowCA$1.44
Beta1.96
11 Month Change-3.77%
3 Month Change8.51%
1 Year Change26.24%
33 Year Change-30.14%
5 Year Change-35.44%
Change since IPO-66.00%

Recent News & Updates

There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Recent updates

There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings

Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth

Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth

The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden

Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive

Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story

Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 11
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Jan 19
Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Sep 22
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Dec 16
Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?

Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially

Aug 21
Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially

Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Aug 04
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?

Shareholder Returns

MDPCA PharmaceuticalsCA Market
7D2.0%-9.9%-0.4%
1Y26.2%21.1%26.1%

Return vs Industry: MDP exceeded the Canadian Pharmaceuticals industry which returned 22.4% over the past year.

Return vs Market: MDP underperformed the Canadian Market which returned 27.3% over the past year.

Price Volatility

Is MDP's price volatile compared to industry and market?
MDP volatility
MDP Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement8.4%
10% most volatile stocks in CA Market17.9%
10% least volatile stocks in CA Market3.0%

Stable Share Price: MDP has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: MDP's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a82Ken d'Entremontwww.medexus.com

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Medexus Pharmaceuticals Inc. Fundamentals Summary

How do Medexus Pharmaceuticals's earnings and revenue compare to its market cap?
MDP fundamental statistics
Market capCA$63.60m
Earnings (TTM)CA$1.52m
Revenue (TTM)CA$151.21m

41.4x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MDP income statement (TTM)
RevenueUS$108.78m
Cost of RevenueUS$46.15m
Gross ProfitUS$62.63m
Other ExpensesUS$61.54m
EarningsUS$1.09m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)0.044
Gross Margin57.57%
Net Profit Margin1.00%
Debt/Equity Ratio142.2%

How did MDP perform over the long term?

See historical performance and comparison